Moreover, by adjusting immunological trajectories to available CD8 + T cell and IL-6 data, our model predicted elevated pro-inflammatory compounds (such as GM-CSF) in both cancer and immunosuppressed patients. This evidence concerns the gene CD8A and cancer.